Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT05425940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Study identification
- NCT ID
- NCT05425940
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 901 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 7, 2022 (Actual)
- Primary completion
- Jun 16, 2026 (Actual)
- Completion
- Jan 31, 2027 (Estimated)
- Last update posted
- Jul 17, 2026
2022 – 2027
United States locations
- U.S. sites
- 45
- U.S. states
- 25
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #65 | Jonesboro | Alabama | 72401 | — |
| Exelixis Clinical Site #30 | Phoenix | Arizona | 85004 | — |
| Exelixis Clinical Site #70 | Tucson | Arizona | 85719 | — |
| Exelixis Clinical Site #9 | Duarte | California | 91010 | — |
| Exelixis Clinical Site #55 | La Jolla | California | 92037 | — |
| Exelixis Clinical Site #77 | Los Angeles | California | 90095 | — |
| Exelixis Clinical Site #105 | Orange | California | 92868 | — |
| Exelixis Clinical Site #80 | Santa Monica | California | 90404 | — |
| Exelixis Clinical Site #5 | Santa Rosa | California | 95403 | — |
| Exelixis Clinical Site #82 | Sylmar | California | 91342 | — |
| Exelixis Clinical Site #58 | Torrance | California | 90505 | — |
| Exelixis Clinical Site #81 | Whittier | California | 90602 | — |
| Exelixis Clinical Site #125 | New Haven | Connecticut | 06510 | — |
| Exelixis Clinical Site #16 | Miami Beach | Florida | 33140 | — |
| Exelixis Clinical Site #60 | Orlando | Florida | 32804 | — |
| Exelixis Clinical Site #4 | Marietta | Georgia | 30060 | — |
| Exelixis Clinical Site #3 | Joliet | Illinois | 60435 | — |
| Exelixis Clinical Site #102 | Indianapolis | Indiana | 46250 | — |
| Exelixis Clinical Site #10 | Westwood | Kansas | 66205 | — |
| Exelixis Clinical Site #47 | Lexington | Kentucky | 40536 | — |
| Exelixis Clinical Site #7 | New Orleans | Louisiana | 70112 | — |
| Exelixis Clinical Site #22 | St Louis | Missouri | 63141 | — |
| Exelixis Clinical Site #8 | Billings | Montana | 59102 | — |
| Exelixis Clinical Site #1 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #15 | Albuquerque | New Mexico | 87131 | — |
| Exelixis Clinical Site #11 | New York | New York | 10016 | — |
| Exelixis Clinical Site #59 | New York | New York | 10029 | — |
| Exelixis Clinical Site #17 | The Bronx | New York | 10461 | — |
| Exelixis Clinical Site #74 | Charlotte | North Carolina | 28204 | — |
| Exelixis Clinical Site #6 | Cincinnati | Ohio | 45219 | — |
| Exelixis Clinical Site #12 | Oklahoma City | Oklahoma | 73142 | — |
| Exelixis Clinical Site #75 | Portland | Oregon | 97210 | — |
| Exelixis Clinical Site #106 | Philadelphia | Pennsylvania | 19107 | — |
| Exelixis Clinical Site #18 | Pittsburgh | Pennsylvania | 15212 | — |
| Exelixis Clinical Site #103 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #24 | Greenville | South Carolina | 29607 | — |
| Exelixis Clinical Site #56 | Chattanooga | Tennessee | 37404 | — |
| Exelixis Clinical Site #76 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #133 | Nashville | Tennessee | 37232 | — |
| Exelixis Clinical Site #450 | Fairfax | Virginia | 22031 | — |
| Exelixis Clinical Site #14 | Roanoke | Virginia | 24014 | — |
| Exelixis Clinical Site #13 | Seattle | Washington | 98101 | — |
| Exelixis Clinical Site #32 | Seattle | Washington | 98104 | — |
| Exelixis Clinical Site #89 | Seattle | Washington | 98109 | — |
| Exelixis Clinical Site #2 | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05425940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05425940 live on ClinicalTrials.gov.